1-8 of 8
Brandon E Kremer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Free
Saad Z. Usmani, Aránzazu Alonso Alonso, Hang Quach, Youngil Koh, Andreas Guenther, Chang-Ki Min, Xiaoou L. Zhou, Morrys Kaisermann, Lukasz M. Mis, Danaè Williams, Anne Yeakey, Geraldine Ferron-Brady, David J. Figueroa, Brandon E. Kremer, Ira Gupta, Wojciech Janowski
Journal: Blood
Blood (2021) 138 (Supplement 1): 2738.
https://doi.org/10.1182/blood-2021-153315
Published: 2021
Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Rakesh Popat, Ajay Nooka, MDMPH, Keith Stockerl-Goldstein, MD, Rafat Abonour, MD, Ryan Ramaekers, MD, Amit Khot, MD, Adam Forbes, MD, Cindy Lee, MD, Bradley Augustson, MBBS FRACP FRCPA, Andrew Spencer, Maria-Victoria Mateos, MD PhD, Bikramjit Chopra, PhD, Rachel Rogers, MS, Deborah A Smith, PharmD, Jacqueline Davidge, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Anne Yeakey, MD, Mala Talekar, MD, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Hang Quach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-139332
Published: 2020
Journal Articles

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Suzanne Trudel, MD, Randy Davis, PhD, Nicole M. Lewis, MSc, Kalpana K. Bakshi, MSc, Bikramjit Chopra, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Laurie Eliason, MPH, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Frank S. Wu, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4.
https://doi.org/10.1182/blood-2020-139785
Published: 2020
Journal Articles

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Paul G. Richardson, MD, Ajay Nooka, MDMPH, Hang Quach, MDFRACP,FRCPA,MBBS, Suzanne Trudel, MD, David Routledge, Kevin Song, MD, Hareth Nahi, MD, Sofia Paul, Josephine Khan, Maria Brouch, Geraldine Ferron-Brady, PhD, Anne Yeakey, MD, Chris Shelton, Rocio Montes de Oca, PhD, L. Mary Smith, Ellie Im, Christoph M Ahlers, Elaine M Paul, Beata Holkova, Ira Gupta, MD, Brandon E. Kremer, MD PhD, Paula Rodriguez-Otero, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-139182
Published: 2020
Journal Articles

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Robert M. Rifkin, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Sebastian Grosicki, MD PhD, Kihyun Kim, MD PhD, Francesco Di Raimondo, MD, Meletios A Dimopoulos, Katja Weisel, MD, Bertrand Arnulf, MD, Roman Hajek, MD, Vania T. M. Hungria, MD PhD, Andrew Spencer, Randy Davis, PhD, Antonio Riccio, PhD MBA, Chanbin Kim, Jodie Wilkes, Ruth Rutledge, Mala Talekar, MD, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Maria-Victoria Mateos, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 53–54.
https://doi.org/10.1182/blood-2020-139181
Published: 2020
Journal Articles

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Free
Justin M. Watts, MD, Terrence J Bradley, MD, Amber Thomassen, Andrew M. Brunner, MD, Mark D. Minden, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Sameem Abedin, MD, Amanda J Baines, Olena Barbash, PhD, Shelby Gorman, Brandon E Kremer, MD PhD, Gautam M. Borthakur, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2656.
https://doi.org/10.1182/blood-2019-130337
Published: 2019
Journal Articles

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Free
Michael Dickinson, MD, Manali Kamdar, MD, Brian J.P Huntly, Carlos Fernández De Larrea, MD PhD, Raul Cordoba, MD PhD, Maria-Victoria Mateos, MD PhD, Adrián Alegre, MD, Won-Seog Kim, MD PhD, Jin Seok Kim, MD PhD, Mark Dawson, MD PhD, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Faisal Basheer, MBBChir, MA, Paolo Gallipoli, PhD, Aristeidis Chaidos, MD PhD, Alejandro Martín, MD, Thierry Horner, PhD, James Winnberg, MS, Lijoy K Mathew, PhD, Jeffrey Botbyl, MS, Natalie Karpinich, PhD, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS,MDPhD, Anastasios Karadimitris, FRCPath, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1682.
https://doi.org/10.1182/blood-2018-99-117089
Published: 2018
Journal Articles

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Free
Gautam Borthakur, MD, Mark A Dawson, MD PhD, Eytan M. Stein, MD, Anastasios Karadimitris, Brian J.P Huntly, MD PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Aristeidis Chaidos, Thierry Horner, PhD, John Brennan, January Baron, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5223.
https://doi.org/10.1182/blood.V128.22.5223.5223
Published: 2016